webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Farletuzumab ecteribulin

  CAS No.: 2407465-18-1   Cat No.: BADC-01611 4.5  

Farletuzumab ecteribulin is an antibody-drug conjugate consisting of the humanized antifolate receptor-alpha (FRα) monoclonal antibody conjugated to eribulin by a cathepsin B-cleavable linker.

Farletuzumab ecteribulin

Structure of 2407465-18-1

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
Antibody-Drug Conjugates (ADCs)

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
MORAb-202

Farletuzumab ecteribulin represents a cutting-edge advancement in the field of targeted cancer therapies, specifically as an antibody-drug conjugate (ADC). Designed to selectively attack cancer cells overexpressing the folate receptor-alpha (FRα), farletuzumab ecteribulin combines the specificity of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutic agents. This ADC leverages the humanized antifolate receptor-alpha monoclonal antibody’s ability to recognize and bind to FRα, a receptor that is abundantly present on the surface of certain cancer cells such as ovarian and endometrial cancers, while largely absent in normal tissues. The conjugation to eribulin, a microtubule dynamics inhibitor, through a cathepsin B-cleavable linker, allows for the precise delivery and release of the cytotoxic payload within the cancer cell environment, minimizing systemic toxicity and enhancing therapeutic efficacy.

In drug discovery, farletuzumab ecteribulin’s development underscores the significant strides made in personalized medicine, providing a framework for creating therapies capable of targeting specific molecular markers associated with various malignancies. The innovation lies in its dual-component structure: the monoclonal antibody component ensures high specificity and preferential binding to cancer cells, while the eribulin component delivers a lethal blow to the internal mechanisms necessary for cancer cell replication. This synergy offers a compelling strategy to circumvent the traditional barriers of chemotherapy resistance and toxicity, presenting a promising addition to oncologists’ arsenal in the fight against resistant cancer forms. Such targeted treatment paradigms are particularly crucial for patients with advanced cancers that have limited treatment options or have become refractory to existing therapies.

The concept of using a cathepsin B-cleavable linker in farletuzumab ecteribulin is particularly ingenious, as it exploits the higher expression and activity levels of cathepsin B enzymes in tumor cells compared to normal cells. Once the ADC is internalized by the cancer cell, the linker is specifically cleaved by cathepsin B, an event that releases the active chemotherapeutic agent eribulin directly into the cellular milieu. This targeted mechanism significantly enhances the drug’s therapeutic window and potency while markedly reducing off-target effects and systemic toxicities. Such advancements in linker technologies play a pivotal role in the pharmacokinetics and pharmacodynamics of ADCs, influencing factors like biodistribution, target accessibility, and payload release kinetics.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Manufacturing Services ADC cGMP Manufacturing ADC Fill/Finish ADC Purification ADC Formulation Development Antibody–Drug Conjugate Solutions ADC Early Discovery ADC Process Development ADC Preclinical Studies

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Current Technical Development Trends in Antibody-Drug Conjugate (ADC) Drugs The Development History of ADC Drugs What are Antibody Drug Conjugates? New FDA-Approved ADC: Disitamab Vedotin for Bladder Cancer New ADC Drug for Lymphoma: Loncastuximab Tesirine Overview of Antibody-Drug Conjugate (ADC) Production Technologies ADC Drugs: Unlocking New Frontiers in Tumor Treatment How to Design A Good ADC Drug? Tivdak: FDA's First Approved Tissue Factor-Targeted Antibody-Drug Conjugate How Endocytosis Influences the Receptor Targeting Mechanism of ADC Drugs?

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: SPDP-PEG8-NHS | Azido-PEG7-amine | Mal-PEG-NHS | MP-Ala-Ala-PAB | Mal-Ala-Ala-PAB-PNP | Farletuzumab ecteribulin
Send Inquiry
Verification code
Inquiry Basket